CJC-1295 dosage reference: typical range 100–500 mcg, 2×/week to daily, cycle 8–12 weeks on, 4 weeks off; use MK-677 as bridge. Titration chart…
Modified GHRH with Drug Affinity Complex (DAC) for extended half-life. CJC-1295 w/DAC has ~8 day half-life; without DAC (Mod GRF 1-29) has 30-minute half-life for more natural pulsing.
Published protocol literature for CJC-1295 describes a typical range of 100–500 mcg, dosed 2×/week to daily, over a cycle of 8–12 weeks on, 4 weeks off; use MK-677 as bridge. Reported half-life: about 30 minutes (no-dac); several days (dac variant).
| Parameter | Reported value |
|---|---|
| Typical dose range | 100–500 mcg |
| Frequency | 2×/week to daily |
| Cycle length | 8–12 weeks on, 4 weeks off; use MK-677 as bridge |
| Half-life | About 30 minutes (no-DAC); several days (DAC variant) |
| Route | Subcutaneous injection (most published protocols) |
| Diluent | Bacteriostatic water |
| Commonly stacked with | Ipamorelin (gold standard GHRH+GHRP stack), IGF-1 LR3 (direct muscle growth), MK-677 (oral bridge) |
Protocols are usually titrated rather than started at the top of the range. The tiers below reflect how CJC-1295 dosing is commonly stepped in the published protocol literature.
| Tier | Dose | Frequency | Notes |
|---|---|---|---|
| Beginner | 100–150 mcg | 2×/week | Gentle start; pair with training |
| Intermediate | 200–250 mcg | 3×/week | Solid gains; combine with GHRP |
| Advanced | 300–500 mcg | Daily or split AM/PM | Elite; monitor IGF-1, watch for water retention |
Concentration in mcg/mL equals vial milligrams multiplied by 1000, divided by the millilitres of bacteriostatic water added. Volume per dose in mL equals the target dose in mcg divided by that concentration. On a U-100 insulin syringe, multiply the volume in mL by 100 to read the units.
| Vial | Bacteriostatic water | Resulting concentration |
|---|---|---|
| 2 mg vial | 1 mL bacteriostatic water | 2,000 mcg/mL |
| 5 mg vial | 1 mL bacteriostatic water | 5,000 mcg/mL |
| 10 mg vial | 2 mL bacteriostatic water | 5,000 mcg/mL |
| State | Conditions | Shelf life |
|---|---|---|
| Lyophilized (Powder) | Refrigerate 2–8°C (36–46°F) or freeze | 12–24 months refrigerated; longer frozen |
| Reconstituted | Refrigerate 2–8°C only; no freezing | 21–30 days typically |
| In Transit | Insulated packaging; ice packs | Minimize time; avoid heat exposure |
| MK-677 (Oral) | Room temp okay; cool/dry preferred | Per manufacturer; typically 12+ months |
Dose ranges on this page summarise published research and practitioner protocol literature for CJC-1295. They are a reference, not medical direction. All peptide products referenced are intended solely for research, investigational, or licensed professional use. They are not FDA-approved and are not intended to diagnose, treat, cure, or prevent any disease. Consult a licensed medical practitioner before any personal or clinical use.
Published protocol literature for CJC-1295 generally describes 100–500 mcg, administered 2×/week to daily. Individual protocols vary and should be set by a licensed practitioner.
2×/week to daily. Frequency is driven by half-life — CJC-1295 has a reported half-life of about 30 minutes (no-dac); several days (dac variant), so shorter-acting compounds are dosed more often.
Typical cycle length reported is 8–12 weeks on, 4 weeks off; use MK-677 as bridge. Cycling exists to limit receptor desensitisation and to create assessment windows, not as a fixed rule.
2mg → 1ml bacteriostatic water; 5mg → 1ml bacteriostatic water; 10mg → 2ml bacteriostatic water. Concentration in mcg/mL equals vial milligrams times 1000 divided by millilitres of bacteriostatic water.
They act on complementary pathways — CJC-1295 on the GHRH receptor and Ipamorelin on the ghrelin/GHS-R receptor — producing a stronger synergistic GH pulse in research models.
DAC (Drug Affinity Complex) extends half-life to several days for tonic GH elevation. No-DAC preserves natural pulsatility, which most research protocols prefer.